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Abstract
Since the 1930s when Kimmelstiel and Wilson ﬁrst described the classic nodular glomerulosclerosis lesions in diabetic kidneys,
nephropathy has been recognized as a major and common complication of diabetes. Nearly 40% of diabetics around the
world have microalbuminuria, a marker of progression to chronic kidney disease (CKD). Diabetic kidney disease (DKD) is
also considered a leading cause of CKD worldwide. Given the signiﬁcant morbidity, mortality, and health-care burden, several
clinical and scientiﬁc societies continue to seek a better understanding of this disease. Screening for microalbuminuria and con-
trolling hyperglycemia remain the pillars for the prevention of diabetic nephropathy. However, evidence from multiple studies
suggests that controlling DKD is more challenging. Some studies suggest that there is variability in the incidence of renal com-
plications among patients despite comparable hyperglycemic control. Therefore, there has been great interest in studying the
inherent, renal protective role of the different antihyperglycemic agents. This review will shed light on the pathophysiology,
screening, and diagnosis of DKD. It will also discuss the treatment and prevention of diabetic nephropathy, with a speciﬁc
focus on comparing the mechanisms, safety proﬁles, and efﬁcacy of the different antihyperglycemic medications.
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Introduction
Diabetes and chronic kidney disease (CKD) are worldwide
public health problems that affect millions of people. A
study speculates that the global prevalence of diabetes melli-
tus would grow from 2.8% in 2000 to nearly 4.4% in 2030,
equivalent to nearly 366million people. The greatest increases
in prevalence are anticipated to occur in theMiddle East, sub-
Saharan Africa, and India (1). Another global epidemiologic
study estimated that 382 million people had diabetes in 2013,
a number that is expected to rise to 592 million by 2035 (2).
This pattern is even more pronounced in the United States
with anticipated 165% increase in the prevalence of diabetes
between 2000 and 2050 (3). Diabetes is a leading cause of
CKDworldwide. Nearly 43% of diabetics in the United States
have microalbuminuria, a marker of progression to CKD.
According to data from National Health and Nutrition
Examination Survey (NHANES), diabetic kidney disease
(DKD) accounts for 39% of prevalent kidney failure (4).
With the increasing prevalence of CKD, the costs of manage-
ment are becoming a public health issue. In 2013, more than
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30 billion dollars from Medicare expenditure were spent on
management of end-stage renal disease (ESRD), 14 billion
of which were due to DKD (4). Given these factors, clinical
societies continue to offer strategies to diagnose and manage
DKD to improve outcomes.
Pathophysiology
Diabetes leads to progressive structural alterations of the
kidneys including extracellular matrix (ECM) accumulation
in the mesangium, glomerular basement membrane, and
tubulointerstitial tissue. The pathophysiology of diabetic
nephropathy is complex and multifactorial. Poor glycemic
control was previously considered the sole driving factor
that drives diabetic nephropathy. However, some studies
demonstrated variability in the development of renal compli-
cations despite comparable hyperglycemic control. For
example, the Diabetes Control and Complications Trial
(DCCT) showed that nearly 30% of type I diabetics and
25%–40% of type II diabetics develop nephropathy despite
intensive glycemic control (5). Variations between ethnic
groups also point to the signiﬁcant role of genetic back-
ground. Relatives of African Americans on renal replacement
therapy secondary to diabetic nephropathy are at ﬁvefold
risk of developing ESRD (6). Additionally, the incidence
of ESRD per capita in African Americans, Hispanics, and
Native Americans is signiﬁcantly higher than the white popu-
lation (7). The incidence of proteinuria among Pima Indians
has also been increasing over the past 36 years. However, the
incidence of progression to ESRD declined after 1990, possibly
due to improved control of risk factors (8). A multicenter study
in 10Asian countries on type II diabetic patients of different eth-
nic groups showed nearly 40% prevalence rate of microalbumi-
nuria, a worrisome marker for developing ESRD (9). Familial
aggregation further supports the role of genetics in development
of ESRD. A large population-based study showed that nearly
23% of incident dialysis patients had relatives with ESRD,
with greater prevalence in African Americans compared to
European Americans (10). Individuals with family history of
ESRDwere also more likely to have diabetes and obesity (11).
AGEs, RAGE, and oxidative stress
Advanced glycosylation end products (AGEs) are the result
of nonenzymatic interaction of sugars like glucose with
amino acid groups of proteins, lipoproteins, and nucleic
acids. Alteration of these cellular components leads to the
formation of various reactive intermediate products like
α-dicarbonyls or oxoaldehydes. These intermediate products
react with intracellular and extracellular proteins to form
irreversibly covalent products, known as AGEs. Circulating
AGEs have been implicated in the pathophysiology of
diabetic nephropathy through mechanisms that are either
receptor-dependent or receptor-independent. AGEs modify
basement membrane proteins, cross-link ECM components,
and increase expression of type IV collagen. These changes
lead to structural alterations of the surface charge, membrane
permeability, proteolytic digestion, and membrane stability.
These changes disrupt intercellular interaction, and hence
cause impairment of tissue function and maintenance (12).
As for the receptor-dependent mechanisms, AGEs interact
with a wide array of receptors on various cell types such as
macrophages, monocytes, endothelial cells, podocytes, tubu-
lar epithelial cells, and smooth muscle cells.
Examples of these receptors are the macrophage scavenger
receptor type I and II, AGE-R1, AGE-R2, AGE-R3, receptor
for AGE (RAGE), and CD36. RAGE is a multi-ligand recep-
tor that mediates intracellular and extracellular signaling
pathways leading to immune response initiation. This receptor
exists in full-length, surface-bound form or as a soluble, trun-
cated form known as soluble RAGE (sRAGE). It is hypothe-
sized that sRAGE competes with full-length RAGE over
ligand binding. The off-balance between the syntheses of
these two forms is one of the AGE-induced nephropathy
mechanisms (13). RAGE activation by AGEs leads to activa-
tion of several signal transduction pathways that lead to the
generation of reactive oxygen species (ROS) and activation
of transcription factors, such as NF-kappaB. Consequently,
NF-kappaB leads to the release of cytokines and growth
factors, including transforming growth factor-β1 (TGF-β1),
interleukin-1β and interleukin-6, insulin-like growth factor-1,
tumor necrosis factor (TNF-α), and platelet-derived growth
factor. These proinﬂammatory growth factors play a key
role in the development of diabetic complications (14). For
example, TGF-β1 leads to the overexpression of mRNA of
glucose transporter 1 (GLUT-1) in mesangial cells, eventually
leading to increased glucose uptake by cells and accelerated
metabolic abnormalities (15). Human studies support the pro-
posed AGE-driven mechanism of diabetic nephropathy. A
study in type I diabetic patients showed that signiﬁcantly ele-
vated levels of ﬂuorescent non-carboxymethyllysine AGEs
correlate with the deterioration of renal function (16). Simi-
larly, levels of AGEs concentrations were increased in type
II diabetic patients with nephropathy (17). As for other
AGE receptors, AGE-R1 and AGE-R3 are considered clear-
ance receptors. AGE-R1 expression is suppressed in diabetic
human beings and mice, suggesting possible protective role
against AGEs. Whereas, AGE-R3 is involved in AGE turn-
over, tissue integrity, and macrophage endocytosis. These
are important compensatory mechanisms that counteract
AGE-induced injury. AGE-R2, like RAGE, is involved in
ﬁbroblast growth factor signaling and the inﬂammatory
response propagation (14).
Metabolic reactions result in the formation of active bypro-
ducts and free radicals known as ROS and reactive nitrogen
species. Inadequate removal of these active molecules leads to
detrimental effects on the cellular level, a process known as
oxidative stress. Examples of these radicals are superoxide, per-
oxyl, hydroxyl, and hydroperoxyl molecules. Superoxide (O2
−)
is a common radical implicated in diabetic complications.
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It is produced by mitochondrial electron transport chain, oxi-
dative phosphorylation, NAD(P)H oxidase, cytochrome P-450,
nitric oxide synthase, and other enzymatic processes (14).
Normally, superoxide radicals are eliminated bymitochondrial
and cytosolic antioxidant defense mechanisms. Impaired
clearance, as in diabetes, leads to the oxidation of membrane
lipids, DNA, proteins, and carbohydrates. These alterations
lead to impaired structure and function of several cellular
components.
There is evidence that diabetic complications arise from
interplay between pathways of AGEs and oxidative stress.
A study showed that diabetic glomerular lesions might
undergo autoxidation by ROS and could be converted to
reactive carbonyl compounds, a subgroup of AGEs (18).
Sodium glucose cotransporter (SGL-2)
A new target for pharmacotherapy of diabetic nephropathy is
sodium–glucose cotransporter-2 (SGLT-2), a major determi-
nant of glucose reabsorption in kidneys. Hyperglycemia and
hyperinsulinemia in early diabetes may lead to increased
expression of SGLT-2, and hence, glucose reabsorption.
This in turn is believed to lead to worsening of hypertension
and maintain hyperglycemia (19). With emergence of
SGLT-2 inhibitors, studies started to examine the possible
protective role of these medications on the kidneys. Increasing
tubuloglomerular feedback, weight loss, lowering blood pres-
sure by osmotic diuresis, and decreasing inﬂammation
through activation ofACE2and angiotensin 1-7/1-9 upregula-
tion are all possiblemechanisms of renal protection by SGLT-2
inhibition (20, 21).
Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that
stimulates insulin secretion from β-islet cells. In addition to its
antihyperglycemic function, GLP-1 has antioxidative protec-
tive role in various tissues. GLP-1 receptor (GLP-1R) is
expressed in pancreas, brain, gut, heart, lung, and kidneys.
Activation of this receptor leads to the stimulation of adeny-
late cyclase which in turn increases the production of cyclic
adenosine monophosphate (cAMP). Increased levels of
cAMP lead to the activation of protein kinase A or guanine
nucleotide exchange factor II (Epac2). This pathway med-
iates insulin secretion and inhibits renal NAD(P)H oxidase,
a major source of oxidative stress. A study showed that
treatment with GLP-1R agonist reduced albuminuria and
mesangial expansion, and reduced expression of glomerular
superoxide. These ﬁndings highlight the protective role of
GLP-1 pathway and its potential as a target for pharma-
cotherapy (22).
Screening and diagnosis
Historically, the term “diabetic nephropathy” has been used
loosely to describe the pathologic effect of diabetes on renal
function. However, there are key deﬁnitions and stages of
this process to assist with diagnosis and management. DKD
is the ﬁnding of proteinuria in a person with diabetes, regard-
less of the presence of pathologic changes or a decreased
glomerular ﬁltration rate (GFR). Diabetic glomerulopathy
on the other hand, is a term reserved for biopsy-proven
renal disease caused by diabetes. Measuring serum albumin
on spot urine tests is the ﬁrst step in screening and diagnosis
of diabetic nephropathy as recommended by most profes-
sional medical societies concerned with diabetes and kidney
disease (23).
Albuminuria
Over the years, the threshold for detection of albuminuria
has changed with the introduction of more sensitive assays.
Albuminuria is reported as albumin excretion rate (AER),
albumin-to-creatinine ratio (ACR), or urinary albumin con-
centration (UAC). Estimation of AER is obtained from
timed collections (expressed in µg/min) or 24-h collection
(expressed in mg/24 h). Urine spot test on the other hand pro-
vides information about ACR (expressed in mg/g creatinine)
and UAC (mg/L). Patients with ACR between 30 and 300
mg/g creatinine on spot urine test (AER 20–200 µg/min or
30–300 mg/24 h) are considered to have microalbuminuria.
Greater degrees of albumin excretion are referred to asmacro-
albuminuria. Variations in ACR with gender are expected,
given lower urine creatinine levels in females, which make
diagnostic thresholds higher in females compared with males.
Sensitivity and speciﬁcity of ACR is between 92% and 94%,
whereas sensitivity and speciﬁcity of UAC is between 89%
and 90%, at discriminator value of 15 mg/L. Although ACR
performs better than UAC statistically, gender variations and
cost make UAC a feasible and accurate option (24). Other
studies suggest that using 17 mg/L of UAC as cutoff for detect-
ing microalbuminuria yields 100% sensitivity and 80% speciﬁ-
city when 24-h urine collection was used as reference (25).
Although patients with microalbuminuria have stable
kidney function, they are at risk of progressing to macroalbu-
minuria and kidney failure (26). Physicians must be cognizant
of the variability in urine albumin excretion. Levels can vary
with exercise, time of day, fever, infection, heart disease,
degree of hyperglycemia at time of collection, pregnancy,
hypertension, and other physiologic processes (27). There-
fore, at least two specimens within 3 to 6 months should be
obtained to conﬁrm staging. Twenty-four-hour and timed
collections are cumbersome and prone to collection errors.
Glomerular filtration rate
GFR should be measured routinely when screening for
diabetic nephropathy. Data from NHANES III (Third
National Health and Nutrition Examination Survey) showed
that nearly 30% of type 2 diabetic patients had worsening
GFR despite absence of albuminuria and retinopathy (28).
This might suggest that albuminuria may not truly reﬂect
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underlying DKD and raises the question of the inevitability
of the disease progression (29). American Diabetes Associa-
tion, National Kidney Foundation, and other medical socie-
ties support annual screening for microalbuminuria, but they
recognize the need for further studies to outline beneﬁts
of this approach. There is still lack of strong evidence about
beneﬁt of screening on major outcomes like ESRD, cardio-
vascular risk, morbidity, and mortality. GFR can be measured
by clearance of endogenous creatinine, insulin clearance,
51Cr-EDTA, 125I-iothalamate, or iohexol techniques. Equa-
tions for estimation of GFR are commonly used in clinical
practice. National Kidney Foundation recommends using
the Modiﬁed Diet in Renal Disease (MDRD) equation, which
is more accurate than the Cockroft–Gault equation (30).
Retinopathy
Concomitant presence of retinopathy has been considered
a helpful ﬁnding in screening for diabetic nephropathy.
However, careful interpretation of the presence or lack of reti-
nopathy must be done. Type I diabetics with nephropathy
almost always have signs of other microvascular complica-
tions like retinopathy or neuropathy (31). This correlation
is not as clear with type II diabetes. For example, in type II
diabetic patients with macroalbuminuria, the positive predic-
tive value (PPV) of retinopathy for diabetic glomerulopathy
ranges between 67% and 100%. However, the negative pre-
dictive value (NPV) is lower, ranging between 20% and
84%. On the contrary, type II diabetic patients with microal-
buminuria had NPV close to 100% and PPV as low as 45%.
Hence, the presence of retinopathy is strongly suggestive of
DKD in type II diabetics with macroalbuminuria, whereas
its absence is highly indicative of non-DKD pathology in
type II diabetics with microalbuminuria (32). Given shared
determinants like poor glycemic control, hypertension, and
hyperlipidemia between diabetic retinopathy and nephropa-
thy, retinopathy should be considered a marker of microvas-
cular involvement rather than a risk factor or diagnostic
ﬁnding for DKD.
Atypical features
Presence of albuminuria and reduced GFR in patients in the
absence of other identiﬁable causes of kidney disease are
enough for establishing diagnosis of DKD. Because diabetes
is a highly prevalent problem, coincidence with other nondia-
betic pathologies is somehow frequent. Therefore, atypical
features such as refractory hypertension, presence of urine
sediments, nephrotic syndrome, rapid disease progression
despite proper glycemic control, and renin–angiotensin sys-
tem blockade should prompt further evaluation for nondia-
betic kidney disease. Workup for concomitant nondiabetic
kidney disease should be tailored based on the patient’s
medical history and risk factors. Kidney biopsy can be very
valuable in evaluating the underlying disease, but bleeding
complications should be considered. Diabetes causes several
pathologic changes to the mesangium, tubules, and vascula-
ture in the kidneys. These changes can be classiﬁed into
four progressive groups according to the Renal Pathology
Society classiﬁcation. Class I is characterized by isolated glo-
merular basement membrane thickening and mild, nonspeci-
ﬁc changes in the mesangium. Mesangial expansion without
diffuse glomerulosclerosis or nodular sclerosis (Kimmelstiel–
Wilson lesions) is seen in class II diabetic nephropathy. Nodular
sclerosis is noted in class II, whereas more severe mesangial
matrix changes are noted in class III. Global glomerulosclero-
sis involving more than 50% of glomeruli is the hallmark of
class IV diabetic nephropathy (33).
Glycemic control: glycemic goals and
measurements
Standard versus intensive control
Diabetic complications including nephropathy are mainly
driven by hyperglycemia-induced vascular injury. Therefore,
glycemic control is in the center of management of DKD
which may slowly progress to ESRD.Major medical societies
like the National Kidney Foundation and the American
Diabetes Association recommend intensive glucose control
to goal hemoglobin A1C (HbA1C) levels <7%. The DCCT
study closely examined the effect of intensive glycemic con-
trol compared with conventional treatment on the develop-
ment of diabetic complications in 1441 subjects with type I
diabetes. Intensive treatment led to about 2% more reduction
in HbA1C in comparison to conventional treatment. After
6.5 years of intensive treatment, the incidence of microalbu-
minuria was reduced by nearly 34% in primary prevention
group (patients with no retinopathy or albuminuria at base-
line) and by 43% in secondary prevention group (patients
with retinopathy and with or without albuminuria but normal
GFR at baseline) (5). In 1993, The Epidemiology of Diabetes
Interventions and Complications (EDIC) observational study
examined 1349 of the original subjects from the DCCT study.
Persistent beneﬁts of intensive glycemic control on albumi-
nuria were noted at 7–8 years after DCCT study closeout
(34). The DCCT/EDIC research group further conﬁrmed
the persistence of these results after median follow-up period
of 22 years (35). These results afﬁrmed that intensive glycemic
control should be pursued early in type I diabetic while keep-
ing patient’s safety in mind and avoiding hypoglycemia.
Similar association between poor glycemic control and
development of albuminuria is noted with type II diabetes.
The Kumamoto study was designed similar to DCCT, with
110 Japanese subjects with type II diabetes. Mean HbA1C
was 7.1% in intensive glycemic control group compared to
9.4% in conventional treatment group. During 6 years, only
7.7% of subjects in the primary prevention group receiving
intensive treatment developed albuminuria compared to
28% in the conventional treatment group. However, subjects
of this trial were relatively young with normal body mass
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index, features that are not necessarily typical or generalizable
to type II diabetes population (36). In 1998, a larger trial that
examined glycemic control effect on nephropathy was the
United Kingdom Prospective Diabetes Study (UKPDS) that
examined 3867 newly-diagnosed type II diabetics. This
study randomized patients to conventional treatment with
diet only versus intensive treatment, which was deﬁned by
goal fasting glucose of 108 mg/dL. Diet, metformin, sulfony-
lurea, insulin, or a combination of agents, were used to
achieve intensive control. Over 10 years, mean HbA1C in
intensive group was 7.0% compared to7.9% in the conven-
tional group, with no signiﬁcant differences in HbA1C
among agents in the intensive group. Relative risk reduction
for the development of microalbuminuria after the duration
of the study was 24%. No differences in risk reduction were
noted between agents in the intensive group (37). Effect of
intensive glycemic control on diabetic complications in a
population of 153 veterans was examined by Veterans Affairs
Cooperative Study of Diabetes Mellitus (VACSDM). After
2 years, the incidence of microalbuminuria in the intensive
treatment group (mean HbA1C of 7.1%) was 17% compared
to 35% in the conventional treatment group (mean HbA1C of
9.2%). Veterans who had microalbuminuria at baseline, and
received intensive treatment, had retardation of the progres-
sion of albuminuria, but still had deterioration of creatinine
clearance at 2 years nonetheless (38). The Veterans Affairs
Diabetes Trail (VADT) was a large study with mean follow-
up of 5.6 years that examined the effects of intensive glycemic
control on vascular complications, mainly cardiovascular
events. The study included nearly 1791 veterans with subopti-
mal diabetes type II control. Although the study showed
no signiﬁcant improvement in cardiovascular events, death,
neuropathy, or retinopathy with intensive control (mean
HbA1C 6.9%) compared to the conventional treatment
group (mean HbA1C 8.4%), there was modest improvement
in the progression of albuminuria. However, this improve-
ment in albuminuria did not translate into prevention of crea-
tinine and GFR worsening (39). Lack of beneﬁt of intensive
control in VADT and VACSDM might be secondary to
shorter follow-up duration (possible delayed effect of glyce-
mic control) or longer duration of diabetes in the included
veterans compared with the newly-diagnosed subjects in
UKPDS.
In the Action in Diabetes and Vascular Disease: Preterax
and Diamicron MR Controlled Evaluation (ADVANCE)
trial, approximately 11,000 patients were randomized to inten-
sive therapy (mean HbA1C 6.5%) compared with standard-
control group (mean HbA1C 7.3%) and were followed up
for median of 5 years. There was no signiﬁcant improvement
in retinopathy or macrovascular outcomes; however, inten-
sive control was associated with 21% relative risk reduction
in new or worsening nephropathy (deﬁned as macroalbumi-
nuria, doubling of creatinine, the need for renal replacement
therapy, or death secondary to renal disease) (40). A follow-
up study of the ADVANCE trial participants showed
persistence of these results with no improvement in retinopa-
thy or macrovascular outcomes but reduction in the progres-
sion to ESRD after median total follow-up of 9.9 years (41).
In the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial, 10,250 patients with type II diabetes were
assigned to intensive (median HbA1C 6.4%) versus standard
glycemic control (median HbA1C 7.5%) and followed up
for median 3.7 years. Because of higher cardiovascular deaths
in the intensive treatment group, patients were switched to
standard treatment and microvascular outcomes were fol-
lowed for the remaining duration of the study (5 years).
There was 29% reduction in developing macroalbuminuria
at transition and study end with the intensive treatment.
There was 19% reduction in development of microalbumi-
nuria at time of transition only with the intensive treatment
(42). Worsening or lack of improvement in the cardiovascular
outcomes from the ACCORD and ADVANCE trials despite
the improvement of nephropathy markers raises concerns
about glycemic control. Intensive glucose control should be
pursued in low-risk groups to avoid harm from hypoglycemia.
As GFR deteriorates, patients become more prone to hypo-
glycemia, secondary to factors such as prolonged action of
insulin, deﬁciency of gluconeogenic precursors, and malnutri-
tion. Hence, caution with glycemic control is warranted espe-
cially in advanced kidney disease.
Limitations of glycemia measurements
Intensive treatment is not the only area of uncertainty in
management of DKD. The reliability of several glycemic
measurement tests has been questioned. HbA1C estimates
time-averaged exposure to glucose for a red blood cell with
120-day life cycle. However, as kidney function deteriorates,
the life cycle of red blood cells becomesmuch shorter, resulting
in falsely lower HbA1C readings (43). Other comorbidities
noted in DKD like acid–base disturbances, anemia, and
erythropoietin deﬁciency may further lower HbA1C (43).
Although imprecise, HbA1C should still be performed to
assist with therapy decisions while being cognizant of its lim-
itations. Serum fructosamine, a test reﬂecting glycemic levels
over 2–3 weeks period, is a possible alternative to HbA1C. It
also reﬂects levels of total glycated serum proteins (43). There-
fore, it might be falsely decreased in DKD secondary to
hypoalbuminemia. Serum concentration of 1,5-anhydroglucitol,
amonosaccharide that is present in nearly all foods, can be uti-
lized to assess glycemic control. Renal reabsorption of this
sugar is dependent on glucose concentration and will be lost
in the urine when blood glucose level is higher than 180 mg/dL
(43). Since many diabetics usually have higher levels of hyper-
glycemia, the utility of this test is very limited. In particular, it
is not recommended in advanced kidney disease. Glycated
albumin is a new marker that reﬂects average glucose levels
over 2–3 weeks. Unlike HbA1C, this test is not affected by
low GFR or anemia. However, there is lack of data regarding
clinical outcomes and correlation of levels with diabetic
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complications. Given the limitations of the aforementioned
tests, self-monitoring of blood glucose remains the most valu-
able tool to guide treatment (43).
Glycemic control: antihyperglycemic agents
Like all diabetic complications, hyperglycemia is the major
contributing factor to vascular injury and renal disease.
Therefore, antihyperglycemic agents are expected to exhibit
their renal protective properties by controlling glucose levels.
However, there is variability in incidence of renal complica-
tions with different antihyperglycemic agents despite compar-
able glycemic control. This observation led to interest in the
inherent renal protective role of these agents that is indepen-
dent of their antihyperglycemic effect (Figure 1). Our current
understanding of these mechanisms is discussed in detail in
the following sections.
Metformin
Metformin, a drug that was ﬁrst used in 1958, is widely pre-
scribed for its hypoglycemic and pleiotropic effects (e.g.,
endothelium protection, polycystic ovarian syndrome, hepa-
tic steatosis, and obesity) (44). Although it is considered the
ﬁrst line of treatment of diabetes, there is controversy about
its safety in patients with kidney disease. For many years,
the fear of developing lactic acidosis in patients with elevated
creatinine deterred a lot of physicians from prescribing the
medication. Previous U.S Food and Drug Administration
(FDA) guideline advised against using metformin in men
with serum creatinine greater than or equal to 1.5 mg/dL
and in women with serum creatinine greater than or equal
to 1.4mg/dL. Several proposed mechanisms link metformin
to lactate accumulation (45). Several mechanisms were pro-
posed for metformin-associated lactic acidosis including inhi-
bition of lactate conversion through gluconeogenesis in the
liver, increased production by glycolysis augmentation, and
activation of anaerobic metabolism of glucose in the intestine
(46). These mechanisms do not lead to signiﬁcant accumula-
tion of lactate at usual metformin therapeutic doses because
of the conversion of lactate back to glucose in the liver via
the Cori cycle (46). Nevertheless, high levels of metformin
reduce lactate clearance by the liver, which might ultimately
lead to metformin-induced lactic acidosis. On the contrary,
several studies questioned whether lactic acidosis in diabetic
patients can solely be attributed to metformin use (46).
Diabetic patients are predisposed to hyperlactemia with lac-
tate levels being double than those in healthy individuals.
Ketoacidosis, heart failure, impaired circulation, liver dys-
function, and physical exercise are all factors contributing
to elevated lactate regardless of metformin use (46). Although
reported in literature, the risk of metformin-induced lactic
acidosis is low and not strongly supported by epidemiologic
evidence. A Cochrane analysis of pooled data from 347
studies examined approximately 70,000 patient-years of met-
formin use. The study revealed no increased risk of fatal or
nonfatal lactic acidosis compared to other antihyperglycemic
treatments (47). Given mounting evidence against the signiﬁ-
cance of “pure” metformin-induced lactic acidosis, the FDA
announced early in 2016 that metformin can be used safely
in patients with stable mild-to-moderate renal impairment.
Metformin use is still contraindicated in patients with GFR
< 30 mL/min/1.73m2, but no dosage adjustments are needed
Figure 1. The different antihyperglycemic agents exhibit their renal protective properties through hyperglycemia-dependent and
independent mechanisms. This ﬁgure attempts to map out our understanding of some of these mechanisms.
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for GFR > 45 mL/min/1.73m2. Initiation of metformin is not
recommended or 50% dosage reduction is advised for GFR
between 30 and 45 mL/min/1.73m2. Frequent monitoring of
renal functions is encouraged and discontinuation of treat-
ment is necessary in the presence of concurrent conditions
that further increase the risk of lactate accumulation (e.g.,
sepsis, acute kidney injury, shock, use of radiographic con-
trast, or myocardial infarction).
Second-generation sulfonylureas
Sulfonylureas are medications that bind to ATP-sensitive K+
(KATP) channels on the membranes of pancreatic beta cells
(48). This leads to trapping of potassium intracellularly, caus-
ing cell depolarization and opening of voltage-gated calcium
channels (48). The inﬂux of intracellular calcium causes
increased secretion of insulin. First-generation sulfonylureas
(e.g., chlorpropamide, tolbutamide, acetohexamide) are not
commonly used, given the risk of hypoglycemia owing to
their long duration of action, risk of hyponatremia, and pos-
sible increased cardiovascular risk. Second-generation sulfo-
nylureas (e.g., glipizide, glyburide, glimepiride) are more
commonly used for diabetes control (49). Glyburide is almost
entirely metabolized by the liver, with elimination of active
metabolites in the urine (49). Impaired renal function may
lead to higher levels of active metabolites and increased risk
of hypoglycemia. Therefore, its use in CKD is not recom-
mended. Interestingly, although metabolized by the liver,
glyburide levels were lower than expected in patients with
CKD while metabolites remained elevated. This was attribu-
ted to possible decreased protein binding leading to rapid
metabolism and elimination of parent drug (49). Rapid meta-
bolism of glyburide might contribute to risk of hypoglycemia
in CKD. Glipizide on the other hand is metabolized by the
liver into inactive metabolites whose clearance is not affected
by renal impairment. Hence, dose adjustments for glipizide
are not necessary. Nonetheless, cautious use of sulfonylureas
is necessary, given their inherent hypoglycemic effect (43).
Thiazolidinediones
Thiazolidinediones (TZDs) (e.g., rosiglitazone, pioglitazone)
are medications that act through the activation of peroxisome
proliferator–activated receptors, a group of nuclear receptors
(50). This process leads to the activation of an intranuclear
pathway that leads to increased transcription of speciﬁc
genes, and consequently, increased storage of fatty acids in
the adipose tissue and increased cellular utilization of glucose
and carbohydrates. Eventually, these changes result in lower
circulating fatty acids and glucose, and improved insulin sen-
sitivity (50). Like sulfonylureas, TZDs are metabolized by the
liver and no dosage adjustments are needed. Relatively small
studies evaluated whether TZDs were more efﬁcacious than
metformin, sulfonylureas, or diet in decreasing albuminuria
in type II diabetics. In a 52-week cardiac safety study, rosigli-
tazone was associated with a decrease in microalbuminuria
compared to glyburide (51). Similar outcomes were noted
when comparing troglitazone with metformin. It is not clear
if TZDs truly have a renal protective role or if these changes
were because of better control of glycemia and hypertension
in the involved subjects. However, side effects such as hyper-
tension, ﬂuid retention, increased fracture risk in women,
bladder cancer, and anemia make its use in CKD unfavorable
(43, 49).
Alpha-glucosidase inhibitors
Acarbose and miglitol are saccharides that bind to key
enzymes in the small intestine that are required for carbohy-
drate absorption (48). Competitive inhibition of these enzymes
leads to reduced glucose absorption from food which leads to
improved serum glucose levels. High frequency of gastroin-
testinal side effects, like ﬂatulence, andmodestHbA1C-lowering
effect (0.5%–1.0%) limit the use of those medications. There
is no need for dose adjustments in mild or moderate
CKD, but they should be avoided when GFR is less than
30 mL/min/1.73m2 due to increased plasma levels. There is
lack of clinical data comparing alpha-glucosidase inhibitors
(AGIs) to other antidiabetic agents in context of renal out-
comes (49, 52).
Dipeptidyl peptidase-4 inhibitors
Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins (e.g.,
sitagliptin, saxagliptin, and linagliptin) are relatively new
hypoglycemic medications that were ﬁrst approved by
the FDA for diabetes treatment in 2006. These medications
inhibit dipeptidyl peptidase whose function is to inactivate
incretins, GLP-1, and gastric inhibitory polypeptide (53).
Subsequently, elevated levels of incretins lead to stimulation
of insulin release and inhibition of glucagon release. These
changes lead to lowering of blood glucose. With the exception
of linagliptin, these medications require dosing adjustments in
renal impairment. Given lower risk of hypoglycemia, DPP-4
inhibitors are potentially useful inCKDpatients, a population
more prone to hypoglycemia (49). The effect of DPP-4 inhibi-
tors on inﬂammation and microvascular complications
was examined by several experimental studies. DPP-4 (also
known as CD26) is expressed in the epithelial cells, renal
tubules, endothelial cells, and as well as leukocytes. It can
bind adenosine deaminase, the deﬁciency of which can lead
to impaired cellular and humoral immunity (54). Therefore,
DPP-4 has been considered a possible culprit of renal injury
and interest in its inhibition became a focus of many studies.
However, the results were conﬂicting. Tofovic et al. (55)
showed that sitagliptin enhanced renovascular response to
angiotensin II in hypertensive rats, an effect that may cause
a decline in renal function. In contrast, a study by Mega et al.
(56) found that chronic low-dose sitagliptin in diabetic rats
led to improvement of glomerular, tubulointerstitial, and vas-
cular lesions. A Japanese study of 36 type II diabetic patients
with inadequate control despite diet, exercise, and medical
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management showed that treatment with sitagliptin led to
lowering of postprandial glucose, HbA1C, glycated albumin,
blood pressure, and ACR after 6 months of sitagliptin. How-
ever, it is not clear if these ﬁndings were independent of
improved glycemic control (57). A pooled analysis of four stu-
dies with 217 subjects with type II diabetes and albuminuria
despite RAAS blockade (ACR of 30–3000 mg/g creatinine)
examined the effect of linagliptin on renal outcomes. This
study concluded that the use of linagliptin in addition to stable
RAAS inhibitors led to signiﬁcant albuminuria reduction,
independent of changes in glucose level or blood pressure
(58). However, none of these studies were designed to speciﬁ-
cally evaluate the effect of linagliptin on microalbuminuria.
The Efﬁcacy, Safety & Modiﬁcation of Albuminuria in Type 2
Diabetes Subjects with Renal Disease with Linagliptin
(MARLINA–T2D™) trial is a recent multicenter, multina-
tional, randomized, double-blind, placebo-controlled trial
that speciﬁcally evaluated the effects of linagliptin on glycemic
control and renal function compared to placebo in total 350
patients. In 2016, the trial concluded and linagliptin was
found to signiﬁcantly reduce HbA1C by 0.6% over 24
weeks. However, no signiﬁcant changes in albuminuria were
noted compared to placebo group (59, 60). Interestingly, in
the Saxagliptin Assessment of Vascular Outcomes Recorded
in Patients with Diabetes Mellitus (SAVOR) trial, patients
receiving saxagliptin had better renal outcomes at the end of
trial compared to placebo group. Approximately 13% of sax-
agliptin group had worse ACR compared to 15.9% of those in
placebo group. Also, more people in saxagliptin group had
improvement in ACR ratio compared to placebo group,
10.7% and 8.7%, respectively. Although the difference in
HbA1C was relatively small, it is unclear whether this desir-
able effect is secondary to glycemic control or inherent property
of saxagliptin (61). The data from SAVOR-Thrombolysis in
Myocardial Infarction (SAVOR-TIMI 53) trial did report
improvement in ACR that is not accounted for by changes
in HbA1C (62).
GLP-1R agonists
GLP-1 is an incretin and neuropeptide that is secreted in the
intestine and hypothalamus in response to the presence of
nutrients. It has potent antihyperglycemic effects such as
enhancement of glucose-dependent insulin secretion, prolif-
eration of β-cells, and inhibition of β-cell apoptosis. It also
slows gastric emptying, increases satiety, and results in body
weight loss (63). GLP-1R agonists also have antioxidative
and pleiotropic properties (64). Liraglutide has been shown
to inhibit NADPH oxidase, NF-κB, and TNFα-induced oxi-
dative stress pathways in endothelial cells (65). In an experi-
mental study, Fujita et al. (23) showed that GLP-1 receptors
are present in glomerular capillary wall, but not tubules, in
mice. Their study also showed that GLP-1R-deﬁcient mice
had higher urinary albumin levels, increased oxidative stress
markers, and more advanced mesangial expansion than
mice in the control group despite comparable hyperglycemia
levels. On the contrary, liraglutide treatment in nephropathy-
prone mice showed reduced albuminuria, mesangial expan-
sion, and superoxide levels. These ﬁndings are suggestive of
direct protective role against oxidative stress (22). Another
experimental study in streptozotocin-induced diabetic rats
showed inhibition of oxidative stress and normalization
of urinary albumin with liraglutide treatment (66). Clinically,
liraglutide has been shown to reduce albuminuria. The
SCALE Diabetes Randomized Trial showed nearly 18%
reduction in ACR in patients receiving 3.0 mg/day dosing
of liraglutide for 56 weeks compared to placebo (67). The
Liraglutide Effect and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER) trial examined
the effect of liraglutide treatment and safety in more than
9000 patients. This trial demonstrated better renal outcomes
in liraglutide treatment group compared to placebo, deﬁned
as composite outcome of reduction in incident macroalbumi-
nuria, doubling of the serum creatinine level, and eGFR
≤ 45 mL/min/1.73m2, need for continuous renal replacement
therapy, or death from renal disease (68). Exenatide is a syn-
thetic version of the salivary hormone exendin-4, which was
ﬁrst identiﬁed in Gila monster in 1992. Exendin-4 has similar
properties to human GLP-1. Similarly, exenatide has been
shown to have renoprotective potential. In a randomized
controlled trial, exenatide was shown to signiﬁcantly reduce
urinary TGF-β1, type IV collagen excretion, and 24-h urinary
albumin after 16 weeks compared to glimepiride (69).
In terms of safety, there are some concerns about the use of
GLP-1R agonists inmoderate and severe CKD. There are few
case reports about acute renal injury with exenatide use. How-
ever, these patients had other possible contributory factors
like gastrointestinal ﬂuid loss and concomitant use of diuretics
and angiotensin-converting enzyme (ACE) inhibitors (70, 71).
The consensus among most medical societies such as the
American College of Endocrinology/American Association
of Clinical Endocrinologists, the National Kidney Founda-
tion, the Canadian Diabetes Association, and the European
Association for the Study of Diabetes is that no dosing adjust-
ments are necessary with mild impairment, cautious use is
needed in moderate kidney, and avoidance is necessary with
severe CKD (49). Although there is lack of a large clinical
study to assess the safety of GLP-1 receptor agonists in
CKD, the emerging evidence (67–69) for their possible renal
protective role might change their future use.
Insulin
Assessing inherent role of insulin in prevention of diabetic
nephropathy is difﬁcult. There are no head-to-head compara-
tive studies to evaluate for inherent, renoprotective role of
insulin compared to other hypoglycemic agents. Improved
renal outcomes with insulin are likely driven by better glycemic
control. The metabolism of insulin in kidney disease is another
important focus which affects dosage requirements (49).
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Nearly 60% of renal insulin clearance occurs by glomerular
ﬁltrations and 40% by peritubular vessels. Once ﬁltrated, it
undergoes extensive reabsorption by the proximal tubule.
As the renal function deteriorates, renal insulin clearance
declines as well due to reduced renal blood ﬂow (72). Patients
with renal failure also have worsening insulin sensitivity, the
mechanism of which is not yet clear. Endogenous insulin
secretion also worsens with renal impairment (72). Metabolic
acidosis and excess parathyroid hormone have been impli-
cated as possible causes of suppressed insulin production
from pancreatic β cells (72). Subsequently, these changes in
metabolism of insulin reﬂect on daily requirements. In early
kidney disease, insulin resistance leads to worsening of hyper-
glycemia and escalation of treatment might be necessary.
However, impaired renal insulin clearance in advanced kid-
ney disease can lead to higher serum insulin concentration,
which in turn can cause hypoglycemia. This may warrant low-
ering of insulin doses or even cessation of insulin therapy (73).
Sodium-coupled glucose transporter type 2 (SGLT2)
inhibitors
SGLT2 inhibitors (e.g., canagliﬂozin, dapagliﬂozin, and
empagliﬂozin) are new medications that inhibit ﬁltered
glucose reabsorption in the renal proximal tubule. This results
in signiﬁcant glycosuria which subsequently leads to low
blood glucose levels, weight loss, lower lipid and uric acid
levels, decreased oxidative stress, and sodium loss (74).
Reduced proximal tubular sodium reabsorption leads to
increased sodium delivery to the macula densa, which acti-
vates tubuloglomerular feedback which in turn causes afferent
vasomodulation and decreased hyperﬁltration. These effects
can be theoretically beneﬁcial in preserving renal function
(75). The increased glycosuria puts patients at increased inci-
dence of dehydration, and genitourinary tract infections, espe-
cially candida infection. Experimental studies also suggest
that SGLT2 inhibitors induce glucagon secretion from alpha
cells, which is counter regulatory mechanism to the medica-
tion-induced hypoglycemia. This increase in glucagon secre-
tion could mean that drops in serum glucose levels are less
than anticipated with the degree of urinary glucose loss.
Another important consideration with the use of SGLT2 inhi-
bitors is that although they improve glycemic control, the
increased glycosuria results in worsening of the typical dia-
betes symptoms such as polyuria, polydipsia, and genitourin-
ary infections (76). Recent clinical trials have shown possible
protective role of SGLT2 inhibitor against macrovascular
and microvascular complications, nephropathy included.
In 2015, the EMPA-REG OUTCOME trial concluded
that empagliﬂozin was associated with better cardiovascular
and mortality outcomes compared with placebo (77). The
trial also examined renal outcomes that were deﬁned
as progression to macroalbuminuria, doubling of serum
creatinine level, eGFR ≤ 45mL/min/1.73m2, initiation of
renal replacement therapy, or death from renal disease.
Approximately 12.7% of the 4124 patients in empagliﬂozin
group had composite incident or worsening of nephropathy,
comparedwith 18.8% of 2061 patients in placebo group. This
corresponds to a signiﬁcant 39% relative risk reduction. Of
note, there was no difference between the two groups in
rates of incident albuminuria in patients with normal albumin
levels at baseline. Some of the limitations of this study are that
it was conducted in patients with high cardiovascular risk.
Generalization of results to diabetic patients with lower cardi-
ovascular risk or to African–American patients might not
reﬂect the same outcomes (75). Although results of this
study are encouraging, more comparative trials with other
hypoglycemic agents are needed to shed light on effectiveness
of SGLT2 inhibitors.
In terms of safety, SGLT2 inhibitors can safely be used in
mild kidney disease, but are contraindicated in severe and
ESRD (49). Dosing adjustments and caution are recom-
mended when using these medications in moderate kidney dis-
ease. Safety aside, these medications are also not ideal with
advanced renal disease because they lose their efﬁcacy, given
their tubular-basedmechanism of action (49). Studies examin-
ing cardiovascular outcomes of other SGLT2 inhibitors like
canagliﬂozin (Canagliﬂozin Cardiovascular Assessment Study
[CANVAS]; ClinicalTrials.gov number: NCT01032629) and
dapagliﬂozin (DECLARE–TIMI58, ClinicalTrials.gov num-
ber: NCT01730534) are still ongoing. Renal and safety out-
comes from those studies will provide more information
about the role of SGLT2 inhibitors in DKD.
Hypertension management
Along with increasing albuminuria and decreasing GFR,
worsening of hypertension is part of the natural process of
DKD. It is one of the most common comorbidities in diabetic
nephropathy, with prevalence of approximately 65% in
patients with macroalbuminuria and insulin-dependent dia-
betics (78). Even in the absence of albuminuria, the prevalence
of hypertension is high at 58% in type II diabetics. These num-
bers increase with progression of albuminuria and CKD and
approach 90% (79). Based on most recent Joint National
Committee (JNC) 8 and KDIGO (Kidney Disease: Improv-
ing Global Outcomes) practice guideline, the goal blood pres-
sure in patients with diabetes should be below 140/90 mmHg
to reduce cardiovascular mortality and progression to CKD.
This recommendation is based on trials that were designed to
examine cardiovascular events and not CKD speciﬁcally. Also,
the trials that supported the goal BP of less than 140/90 mmHg
in preventing CKD were in non-DKD patients and included
African Americans predominantly. Therefore, the relevance
of this recommendation was questioned by experts, and
many physicians continue to aim for goal blood pressure of
130/80 mmHg in diabetics with moderate or severe albumi-
nuria (80). The consensus is that more studies are needed to
identify blood pressure targets in management of DKD.
Kinaan M et al.
Journal of Renal and Hepatic Disorders 2017; 1(2): 10–24 18
As for the choice of antihypertensive medications, ACE
inhibitors and angiotensin receptor blockers (ARBs) have
been shown by several studies to decrease urine albumin
excretion and delay progression of kidney disease in diabetes
type I and II. The Irbesartan in Diabetic Nephropathy Trial
(IDNT) was a randomized controlled trial that evaluated
the effect of Irbesartan on progression of DKD. Approxi-
mately 1700 patients were randomized to irbesartan, amlodi-
pine, or placebo groups. Although rates of ESRD and death
were not signiﬁcantly different between the groups, irbesartan
led to signiﬁcant slowing of rate of creatinine doubling (81).
Another landmark study is the Reduction in Endpoints
in NIDDM with the Angiotensin Antagonist Losartan
(RENAAL), which randomized 1513 patients with type II
diabetes to losartan and placebo groups. The study showed
that losartan was associated with reduction of doubling of
creatinine but had no effect on death (82). Unlike IDNT,
there was reduction in occurrence of ESRD with losartan
treatment. The Irbesartan in MicroAlbuminuria (IRMA)
showed signiﬁcant reduction in rates of progression from
microalbuminuria to macroalbuminuria with 300 mg irbesar-
tan compared to placebo, further supporting the protective
role of ARBs (83). As for primary prevention of albuminuria,
the Bergamo Nephrologic Diabetes Complications Trial
(BENEDICT) compared trandolapril, verapamil, combina-
tion therapy, and placebo. The study concluded that trando-
lapril monotherapy and combination therapy were associated
with lower incidence ofmicroalbuminuria compared to verapa-
mil alone and placebo (79). This suggests that treatment with
ACE inhibitors could delay onset of microalbuminuria in
type II diabetics. The Randomized Olmesartan and Diabetes
MicroAlbuminuria Protection (ROADMAP) study showed
similar ﬁndings to BENEDICT (84). The Diabetics Exposed
to Telmisartan and Enalapril (DETAIL) trial demonstrated
non-inferiority of ARBs to ACE inhibitors in preventing
GFR decline in type II diabetics. Given the protective role
of these medications individually, several studies were inter-
ested in assessing combination therapy of ARBs and ACE
inhibitors (85). The Candesartan and Lisinopril Microalbu-
minuria (CALM II) study showed that combination therapy
was not different from maximization of initial monotherapy
in terms of blood pressure control and albuminuria after 1
year (86). The Ongoing Telmisartan Alone and in Combina-
tion with Ramipril Global Endpoint Trial (ONTARGET)
showed higher rates of hyperkalemia, decline in GFR, and
incidence of acute kidney failure requiring dialysis with com-
bination therapy (87). The VA NEPHRON-D study exam-
ined the rates of acute kidney injury with combined losartan
and lisinopril therapy in nearly 1400 veterans. Higher rates
of acute renal injury were noted with combination therapy
than monotherapy (88). Based on these results, combination
of ACE inhibitors and ARBs should not be offered to
patients, given lack of strong evidence that shows beneﬁt
and potential harm.
Direct renin inhibitors like aliskiren can lower blood pres-
sure and albuminuria in diabetic patients. A study showed
that combination therapy with aliskiren and irbesartan
achieved lower rates of albuminuria than monotherapy or
placebo despite comparable blood pressure control (79).How-
ever, theAliskiren Trial in Type 2DiabetesUsing Cardiorenal
Endpoints (ALTITUDE) trial showed increased risk of
adverse events and no preservation of renal function. The
trial included 8561 diabetic patients with either preexisting
cardiac or renal condition. Patients were randomized to
300 mg/day of aliskiren or placebo. All patients were
receiving an ACE inhibitor or ARB at baseline as well.
After 32 months, 18.3% of patients in aliskiren group reached
primary endpoint of cardiovascular event, death from renal or
cardiac cause, doubling of creatinine, or onset of ESRD, com-
pared to only 17.1% in placebo group. Adverse effects like
hyperkalemia were signiﬁcantly higher in aliskiren group
(13.2% vs. 10.2%). Based on these results, the trial was stopped
early (89).
Nondihydropyridine calcium channel blockers, diltiazem
and verapamil, appear to have antiproteinuric effects. A
small study of 30 type 2 diabetes patients showed that addition
of verapamil to lisinopril led to much greater reductions in
rates of albuminuria (90). Although promising, there is still
no strong evidence about the role of nondihydropyridine
calcium channel blockers in management of DKD. Dihydro-
pyridine calcium channel blockers have an even more
obscure role in DKD, with studies showing variable effects
ranging from worsening proteinuria to no effect to improved
albuminuria.
Another area of interest in hypertension management in
DKD is the role of mineralocorticoid receptor antagonists.
In some patients on ACE inhibitors and ARBs, plasma aldos-
terone levels increase to pretreatment level which may lead
to detrimental changes in the kidneys like worsening of
albuminuria and hypertension. This phenomenon is referred
to as “aldosterone escape.” Using mineralocorticoid receptor
antagonists like spironolactone as an add-on therapy to
ACE inhibitor or ARB has been shown to reduce albuminuria
in several small, randomized controlled trials. However,
increased risk of hyperkalemia raises concerns about combin-
ing ACE inhibitors/ARBs with mineralocorticoid receptor
antagonists (79).
Bardoxolone methyl was an experimental antioxidant
medication that was shown to have beneﬁts in animal models
with kidney injury. There was interest in the possible protec-
tive role of this medication in DKD. In the Bardoxolone
Methyl Treatment: Renal Function in CKD/Type 2 Diabetes
(BEAM) trial, nearly 220 patients with type 2 diabetes and
low GFR were randomized to bardoxolone methyl treatment
or placebo. GFR improved in patients receiving bardoxolone
methyl treatment, an effect that was not observed in placebo
group (91). However, the Bardoxolone Methyl Evaluation in
Patients with Chronic Kidney Disease and Type 2 Diabetes
Mellitus (BEACON) trial showed that bardoxolone methyl
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not only did not improve ESRD or cardiovascular death
outcomes but also increased the rate of cardiovascular
events (a composite of cardiovascular death, heart failure
hospitalization, nonfatal stroke, and nonfatal myocardial
infarction). Bardoxolone methyl was also associated with
higher blood pressure and albuminuria in the BEACON
trial (92).
Despite the continuous interest in ﬁnding newer antihyper-
tensive medications that could slow the progression of DKD,
ACE inhibitors and ARBs remain the most important tools in
our arsenal at this time in controlling blood pressure and
albuminuria in diabetic nephropathy.
Hyperlipidemia management
Hyperlipidemia is common in patients with diabetes, a
condition that is exacerbated with impaired renal function.
Elevated cholesterol not only promotes atherosclerosis but
also accelerates glomerulosclerosis in CKD. The clinical
impact of this process on diabetic nephropathy is not clear.
A study in type I diabetics showed that total cholesterol con-
centration above 220 mg/dL and diastolic pressure above
85 mmHg were the strongest predictors for progressive
renal disease (93). Statins remain the most frequently used
lipid-lowering medications in managing hyperlipidemia in
diabetic patients. According to the 2013 ACC/AHA guide-
lines for assessment of cardiovascular risk and management
of atherosclerotic cardiovascular disease, diabetic patients
would beneﬁt from lipid-lowering medications. Different
intensities of statins are used in diabetics based on the
10-year atherosclerotic cardiovascular disease (ASCVD)
risk estimate. Patients with DKD have comparable magni-
tude of low-density lipoprotein cholesterol reduction with
statin therapy to those with normal kidney function. Cardio-
vascular events and mortality in patients with CKD are
reduced with lipid-lowering treatment, statins or statin/ezeti-
mibe, compared to placebo (94). Although statin therapy
improves cardiovascular outcomes, it has no beneﬁcial effect
on the progression of preexisting kidney disease (95). KDIGO
guidelines recommend initiating statin therapy in patients
with nondialysis-dependent CKD; however, clinical trials
showed no beneﬁts in prevention of cardiovascular death in
patients on dialysis. Although there is no strong evidence to
support initiating statin therapy in dialysis patients, it is clini-
cally sound to continue statin therapy in patients with CKD
who progress to ESRD. A large meta-analysis also showed
that statins have a reasonable safety proﬁle in CKD with
no signiﬁcant adverse events (94). Fenoﬁbrates have
been shown to slow down progression of albuminuria in
type II diabetics. Possible mechanisms for their renoprotec-
tive role are suppression of inﬂammation, decreased produc-
tion of type 1 collagen in mesangial cells, and increased
activity of perioxisome proliferator–activated receptor–
alpha (96–98).
Conclusion
DKD remains the leading cause of CKD despite considerable
progress in our understanding of its pathophysiology and risk
factors. The focus remains on early screening and prevention
of microalbuminuria through the adoption of multiple inter-
ventions and strategies targeting control of hyperglycemia,
hypertension, and hyperlipidemia. There is promising evi-
dence that some antihyperglycemic agents, like SGLT-2 inhi-
bitors, have inherent renal protective properties that could
add to the arsenal of diabetes control. However, more studies
that are speciﬁcally designed to examine the renal outcomes
of the different antihyperglycemic agents are necessary.
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